<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849910</url>
  </required_header>
  <id_info>
    <org_study_id>VBP101</org_study_id>
    <nct_id>NCT04849910</nct_id>
  </id_info>
  <brief_title>Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML</brief_title>
  <official_title>A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vor Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vor Biopharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in&#xD;
      participants with AML who are undergoing human leukocyte antigen (HLA)-matched allogeneic&#xD;
      hematopoietic cell transplant (HCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High risk acute myeloid leukemia (AML) frequently relapses despite hematopoietic stem cell&#xD;
      transplant (HCT). Post-HCT targeted therapy to reduce relapse is limited by toxicity to the&#xD;
      engrafted cells. VOR33, an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and&#xD;
      progenitor cell (HSPC) therapy product, lacking the CD33 protein, is being investigated for&#xD;
      participants with CD33+ AML at high risk for relapse after HCT to allow post-HCT targeting of&#xD;
      residual CD33+ acute AML cells using Mylotarg™ without toxicity to engrafted VOR33 cells.&#xD;
      Participants will undergo a myeloablative HCT with matched related or unrelated donor&#xD;
      CD34+-selected hematopoietic stem and progenitor cells (HSPCs) engineered to remove CD33&#xD;
      expression (VOR33 product). Mylotarg™ will be given after engraftment for up to 4 cycles. The&#xD;
      primary endpoint assessing safety of VOR33 will be the incidence of successful engraftment at&#xD;
      28 days. Part 1 of this study will evaluate the safety of escalating Mylotarg™ dose levels to&#xD;
      determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2 will&#xD;
      expand the number of participants to evaluate the Mylotarg™ RP2D.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of neutrophil engraftment</measure>
    <time_frame>Day 28</time_frame>
    <description>Cumulative incidence of patients who achieve neutrophil engraftment (first day of 3 consecutive days of absolute neutrophil count (ANC) ≥500 cells/mm3) by Day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Time to neutrophil engraftment after HCT from Day 0; calculated as the first day of 3 consecutive laboratory values obtained on separate days where the ANC is ≥500 cells/mm3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet recovery</measure>
    <time_frame>Up to approximately 60 days</time_frame>
    <description>Time to platelet recovery defined as time from Day 0 to achieve platelet count ≥20,000/μL without transfusion in prior 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVHD Grade (G) G2-G4 and G3-G4</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD (all and moderate-severe)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary and secondary graft failure</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Incidence of primary and secondary graft failure measured by day 28 post HCT. Secondary graft failure is defined as initial neutrophil engraftment by Day 28 followed by subsequent decline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicities to determine the MTD and RP2D of Mylotarg™</measure>
    <time_frame>Approximately day 60 until 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of transplant-related mortality (TRM) post HCT</measure>
    <time_frame>Day 100, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD33-negative myeloid cells</measure>
    <time_frame>Day 28, 60, 100, 180, and Months 12 and 24</time_frame>
    <description>Percent donor myeloid chimerism and CD33-negative myeloid cells in peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free Survival (RFS)</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>Cumulative incidence of RFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>OS defined as the time from HCT to the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VOR33 infusion followed by Mylotarg Dose Level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VOR33 infusion followed by Mylotarg Dose Level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VOR33 infusion followed by Mylotarg Dose Level 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VOR33</intervention_name>
    <description>Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mylotarg</intervention_name>
    <description>Infusion of Mylotarg</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>gemtuzumab ozogamicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be ≥18 and ≤70 years of age.&#xD;
&#xD;
          2. Must have confirmed diagnosis of AML in first or second complete remission (CR1 or&#xD;
             CR2) or have bone marrow blasts ≤10% without circulating blasts.&#xD;
&#xD;
          3. AML sample from the patient must have evidence of CD33 expression (&gt;0%)&#xD;
&#xD;
          4. AML must have intermediate or high-risk disease-related genetics and the presence of&#xD;
             minimal residual disease (MRD). Subjects in CR2 or with persistent morphologic blasts;&#xD;
             may have favorable disease-related genetics.&#xD;
&#xD;
          5. Candidate for HLA-matched allogeneic HCT using a myeloablative conditioning regimen.&#xD;
&#xD;
          6. Must have a related or unrelated stem cell donor that is a 10/10 match for HLA-A, -B,&#xD;
             -C, -DRB1 and -DQB1.&#xD;
&#xD;
          7. Must have adequate performance status and organ function as defined below:&#xD;
&#xD;
               1. Performance Status: Karnofsky score of ≥70.&#xD;
&#xD;
               2. Cardiac: left ventricular ejection fraction (LVEF) ≥50%&#xD;
&#xD;
               3. Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO), forced vital&#xD;
                  capacity (FVC), and forced expiratory volume in one second (FEV1) ≥66%.&#xD;
&#xD;
               4. Renal: estimated glomerular filtration rate (GFR) &gt;60 mL/min&#xD;
&#xD;
               5. Hepatic: total bilirubin &lt;1.5 × ULN, or if ≥1.5 × ULN direct bilirubin &lt;ULN and&#xD;
                  ALT/AST &lt;1.5 × ULN (per institutional criteria).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior autologous or allogeneic stem cell transplantation.&#xD;
&#xD;
          2. Presence of the following disease-related genetics: t(15; 17)(q22; q21), or t(9;&#xD;
             22)(q34; q11), or other evidence of acute promyelocytic leukemia or chronic myeloid&#xD;
             leukemia.&#xD;
&#xD;
          3. Prior treatment with Mylotarg™ (gemtuzumab ozogamicin).&#xD;
&#xD;
          4. Active central nervous system (CNS) leukemia or history of other active&#xD;
             malignancy(ies).&#xD;
&#xD;
          5. Patients diagnosed with Gilbert's syndrome.&#xD;
&#xD;
          6. Uncontrolled bacterial, viral, or fungal infections; or known human immunodeficiency&#xD;
             virus (HIV), Hepatitis B, or Hepatitis C infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Maroge</last_name>
      <phone>858-246-0682</phone>
      <email>jmaroge@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Divya Koura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guenther Koehne, MD, PhD</last_name>
      <phone>786-527-8427</phone>
      <email>guentherk@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Guenther Koehne, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Suh, MD</last_name>
      <phone>551-996-5863</phone>
      <email>Hyung.Suh@hmhn.org</email>
    </contact>
    <investigator>
      <last_name>Hyung Suh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Cho, MD</last_name>
      <phone>646-608-3785</phone>
    </contact>
    <investigator>
      <last_name>Christina Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cancer Information Service Line</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Brenda Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roland Walter, MD, PhD, MS</last_name>
      <email>rwalter@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Roland Walter, MD, PhD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadia Bambace, MD</last_name>
      <phone>514-252-3404</phone>
      <email>nadia.bambace@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Nadia Bamace, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Hematopoietic stem cell transplant</keyword>
  <keyword>HCT</keyword>
  <keyword>CD33</keyword>
  <keyword>Allogeneic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

